GSK in breach for misleading prescription information on Omjjara: industry body
London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards in the marketing and prescription information of its drug Omjjara, according to an industry self-regulatory body on Tuesday.
Omjjara is prescribed for the treatment of symptoms such as an enlarged spleen in adults suffering from myelofibrosis - a rare bone marrow blood cancer - and moderate to severe anaemia.
The prescribing information provided for the drug misled women using hormonal contraceptives about the necessity for extra precautions to prevent pregnancy, the Prescription Medicines Code of Practice Authority (PMCPA) said.
According to Reuters, a GSK spokesperson said, "We take adherence to industry codes and regulations very seriously".
Next Story